Mergers & Acquisitions

Biopharmaceutical company acquires minority interest in TKT Europe-5S AB

Published in Gene Therapy Weekly, November 25th, 2004

Transkaryotic Therapies, Inc. (TKTX) has completed the purchase of the 20% equity interest in TKT Europe-5S AB held by the founding European executives of TKT Europe-5S for $61 million. With this purchase, TKT now owns 100% of TKT Europe-5S.

The purchase price was based on a predefined formula included in the original agreement between TKT and the founding European executives.

The company will account for the acquisition of TKT Europe-5S's minority interest as a step acquisition in the fourth quarter of 2004. TKT expects that the majority of the purchase price will be allocated to tangible and intangible assets.

TKT formed TKT...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2004-11-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry